APRI -- Hilarious games pulled again. The people following this company are about as misguided as the PPHM people.
30-Dec-2011
Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement. On December 30, 2011, Apricus Biosciences, Inc. (the "Company") entered into an exclusive license agreement (the "Agreement") with Stellar Pharmaceuticals Inc. ("Stellar"), granting Stellar the exclusive rights to market MycoVa? (terbinafine), the Company's drug candidate for the treatment for onychomycosis (nail fungal infection), in Canada.
Under the terms of the Agreement, Stellar will assist the Company in the filing of a New Drug Submission in Canada for MycoVa? for the treatment of onychomycosis. If the application is approved, Stellar will have the exclusive rights to commercialize MycoVa in Canada. Over the term of the Agreement, the Company has the right to receive up to approximately $8 million (Canadian) in up-front, regulatory and sales milestone payments, plus tiered, royalty payments based on Stellars' sales of the product in Canada, if approved for commercialization.
biz.yahoo.com/e/111230/apri8-k.html
But wait...they slipped this juicy bit in a different filing tonight. Stockholders will have the lucky opportunity to buy more shares!
$20,000,000 Apricus Biosciences, Inc. Common Stock
We have entered into a sales agreement (“Sales Agreement”) with Ascendiant Capital Markets, LLC (“Ascendiant”) relating to shares of our common stock, $0.001 par value per share that may be offered by this prospectus supplement and the accompanying prospectus. In accordance with the terms of the Sales Agreement, we may offer and sell an aggregate of up to $20,000,000 of common stock from time to time through Ascendiant, as sales manager.
Market Data 
Markets 
AI
